Skip to main content

Advertisement

SpringerLink
Log in

The role of SERMs in the management of postmenopausal osteoporosis

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lindsay R., Hart D.M., Forrest C., Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980, ii: 1151–1153.

    Article  Google Scholar 

  2. Christiansen C., Christensen M.S., McNair P.L., Hagen C., Stocklund K.E., Transbøl I. Prevention of early menopausal bone loss: Conducted 2-year. Eur. J. Clin. Invest. 1980, 10: 273–279.

    Article  CAS  PubMed  Google Scholar 

  3. Hutchinson A., Polansky S.M., Feinstein A.R. Postmenopausal estrogens protect against fractures of the hip and distal radius: a case control study. Lancet 1979, ii: 705–709.

    Article  Google Scholar 

  4. Weiss N.S., Ure C.L., Ballard J.H., Williams A.R., Daling J.R. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogens. N. Engl. J. Med. 1980, 303: 1195–1198.

    Article  CAS  PubMed  Google Scholar 

  5. Kiel D.P., Felson D.T., Anderson J.J., Wilson P.W.F., Moskowitz M.A. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N. Engl. J. Med. 1987, 317: 1169–1174.

    Article  CAS  PubMed  Google Scholar 

  6. Quigley M.E.T., Martin P.L., Burnier A.M., Brooks P. Estrogen therapy arrests bone loss in elderly women. Am. J. Obstet. Gynecol. 1987, 156: 1516–1523.

    Article  CAS  PubMed  Google Scholar 

  7. Schneider D.L., Barrett-Connor E.L., Morton D.J. Timing of postmenopausal estrogen for optimal bone mineral density. JAMA 1997, 277: 543–547.

    Article  CAS  PubMed  Google Scholar 

  8. Michaelsson K., Baron J.A., Farahmand B.Y., Johnell O., Magnusson C., Persson P.-G., Persson I., Ljunghall S. Hormone replacement therapy and risk of hip fracture: a case-control study. BMJ 1998, 316: 1858–1863.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E., Stampfer M.J., Hennekens C., Rosner B., Speizer F.E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 1995, 332: 1589–1593.

    Article  CAS  PubMed  Google Scholar 

  10. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350: 1047–1059.

    Article  Google Scholar 

  11. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996, 348: 977–980.

    Article  CAS  PubMed  Google Scholar 

  12. Jick H., Derby L.E., Myers M.W., Vasilakis C., Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal estrogens. Lancet 1996, 348: 981–983.

    Article  CAS  PubMed  Google Scholar 

  13. Grodstein F., Stampfer J.J., Goldhaber S.Z. Prospective study of exogenous hormones and risk of pulmonary embolism. Lancet 1996, 348: 983–987.

    Article  CAS  PubMed  Google Scholar 

  14. Gutthann S.P., Garcia-Rodriguez L.A., Castellsague J., Oliart A.D. Hormone replacement therapy and risk of thromboembolism: population based case-control study. BMJ 1997, 314: 796–800.

    Article  CAS  Google Scholar 

  15. Beresford S.A.A., Weiss N.S., Voight L.F., McKnight B. Risk of endometrial cancer in relation to use of estrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997, 349: 458–461.

    Article  CAS  PubMed  Google Scholar 

  16. Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Willett W.C., Rosner B., Speizer F.E., Hennekens C.H. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 1996, 335: 453–461.

    Article  CAS  PubMed  Google Scholar 

  17. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280: 605–613.

    Article  CAS  PubMed  Google Scholar 

  18. Henderson V.W. The epidemiology of estrogen replacement therapy and Alzheimer’s disease. Neurology 1997, 48 (Suppl. 7): S27–S35.

    Article  CAS  PubMed  Google Scholar 

  19. Newcomb P.A., Storer B. Postmenopausal hormone use and risk of large bowel cancer. J. Natl. Cancer. Inst. 1995, 87: 1067–1071.

    Article  CAS  PubMed  Google Scholar 

  20. Compston J.E. The therapeutic use of bisphosphonates. BMJ 1994, 309: 711–715.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Storm T., Kollerup G., Thamsborg G., Genant H.K., Sørensen O.H. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J. Rheumatol. 1996, 23: 1560–1564.

    CAS  PubMed  Google Scholar 

  22. Liberman U.A., Weiss S.R., Bröll J., Minne H.W., Quan H., Bell N.H., Rodriguez-Portales J., Downs R.W., De Queker J., Favus M., Seeman E., Recker R.R., Capizzi T., Santora A.C., Lombardi A., Shah R.V., Hirsch L.J., Karpf D.B. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 1995, 333: 1437–1443.

    Article  CAS  PubMed  Google Scholar 

  23. Herd R.J.M., Balena R., Blake G.M., Ryan P.J., Fogelman I. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. Am. J. Med. 1997, 103: 92–99.

    Article  CAS  PubMed  Google Scholar 

  24. Hosking D., Chilvers C.E.D., Christiansen C., Ravn P., Wasnich R., Ross P., McClung M., Balske A., Thompson D., Daley M., Yates J. Prevention of bone loss with alendronate in postmenopausal women under sixty years of age. N. Engl. J. Med. 1998, 338: 485–492.

    Article  CAS  PubMed  Google Scholar 

  25. Meunier P.J., Boivin G. Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone 1997, 21: 373–378.

    Article  CAS  PubMed  Google Scholar 

  26. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., Gnsrud K.E. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348: 1535–1541.

    Article  CAS  PubMed  Google Scholar 

  27. Ensrud K.E., Black D.M., Palermo L., Bauer D.C., Barrett Connor E., Quandt S.A., Thompson D.E., Karpf D.B. Treatment with alendronate prevents fractures in women at highest risk - Results from the fracture intervention trial. Arch. Intern. Med. 1997, 157: 2617–2624.

    Article  CAS  PubMed  Google Scholar 

  28. Storm T., Thamsborg G., Steiniche T., Genant H.K., Sørensen O.H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med. 1990, 322: 1265–1271.

    Article  CAS  PubMed  Google Scholar 

  29. Watts N.B., Harris S.T., Genant H.K., Wasnich R.D., Miller P.D., Jackson R.D., Licata A.A., Ross P., Woodson G.C., Yanover M.J., Mysiw J., Kohse L., Rao M.B., Steiger P., Richmand B., Chesnut C.H. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. 1990, 323: 72–79.

    Google Scholar 

  30. Van Staa T.P., Abenhaim L., Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. Br. J. Rheumatol. 1998, 37: 87–94.

    Article  PubMed  Google Scholar 

  31. de Groen P.C., Lubbe D.F., Hirsch L.J., Daifotis A., Stephenson W., Freedholm D., Pryor-Tillotson S., Seleznick M.J., Pinkas H., Wang K.K. Esophagitis associated with the use of alendronate. N. Engl. J. Med. 1996, 335: 1016–1021.

    Article  PubMed  Google Scholar 

  32. Meunier P.J., Confavreux E., Tupinon I., Hardouin C., Delmas P.D., Balena R. Prevention of early postmenopausal bone loss with cyclical etidronate therapy a double-blind, placebocontrolled study and 1-year follow-up. J. Clin. Endocrinol. Metab. 1997, 82: 2784–2791.

    CAS  PubMed  Google Scholar 

  33. Overgaard K., Hansen M.A., Jensen S.B., Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992, 305: 556–561.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Kanis J.A., McCloskey E.V. Effect of calcitonin on vertebral and other fractures. Q. J. Med. 1999, 92: 143–149.

    Article  CAS  Google Scholar 

  35. Kanis J.A., Johnell O., Gullberg B., Allander E., Dilsen G., Gennari C., Vaz A.A.L., Lyritis G.P., Mazzuoli G., Miravet L., Passeri M., Cano R.P., Rapado A., Ribot C. Evidence for the efficacy of bone active drugs in the prevention of hip fracture. BMJ 1992, 305: 1124–1128.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Stock J.L., Avioli L.V., Baylink D.J., Chesnut C., Genant H.K., Maricic M.J., Silverman S.L., Schaffer A.V., Feinblatt J. Calcitonin-salmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women: three-year interim results of the PROOF study. J. Bone Miner. Res. 1997, 12 (Suppl. 1): S149.

    Google Scholar 

  37. Compston J.E. Vitamin D deficiency in the elderly: time for action? BMJ 1998, 317: 1466–1467.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Chapuy M.C., Arlot M.E., Duboeuf F., Brun J., Crouzet B., Arnaud S., Delmas P.D., Meunier P.J. Vitamin D3 and calcium to prevent hip fracture in elderly women. N. Engl. J. Med. 1992, 327: 1637–1642.

    Article  CAS  PubMed  Google Scholar 

  39. Dawson-Hughes B., Harris S.S., Krall E.A., Dallal G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N. Engl. J. Med. 1997, 337: 670–676.

    Article  CAS  PubMed  Google Scholar 

  40. Heikinheimo R.J., Inkovaara J.A., Harju E.J. Annual injection of vitamin D and fracture of aged bones. Calcif. Tissue Int. 1992, 51: 105–110.

    Article  CAS  PubMed  Google Scholar 

  41. Lips P., Graafmans W.C., Ooms M.E., Bezemer P.D., Bouter L.M. Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial. Ann. Intern. Med. 1996, 124: 400–406.

    Article  CAS  PubMed  Google Scholar 

  42. Tilyard M.W., Spears G.F.S., Thomson J., Dovey A. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N. Engl. J. Med. 1992, 326: 357–362.

    Article  CAS  PubMed  Google Scholar 

  43. Orimo H., Shiraki M., Hayashi Y., Hoshino T., Onaya T., Miyazaki S. Effects of 1alpha-hydroxyvitamin D3 on lumbar bone density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif. Tissue Int. 1994, 54: 370–376.

    Article  CAS  PubMed  Google Scholar 

  44. Ott S., Chesnut C.H. Calcitriol is not effective in postmenopausal osteoporosis. Ann. Intern. Med. 1989, 110: 267–274.

    Article  CAS  PubMed  Google Scholar 

  45. Cumming R.G. Calcium intake and bone mass: a quantitative review of the evidence. Calcif. Tissue Int. 1990, 47: 194–201.

    Article  CAS  PubMed  Google Scholar 

  46. Compston J.E. The role of vitamin D and calcium supplementation in the prevention of osteoporotic fractures in the elderly. Clin. Endocrinol. 1995, 43: 393–405.

    Article  CAS  Google Scholar 

  47. Cumming R.G., Nevitt M.C. Calcium for prevention of osteoporotic fractures in postmenopausal women. J. Bone Miner. Res. 1997, 12: 1321–1329.

    Article  CAS  PubMed  Google Scholar 

  48. Kleerekoper M. Fluoride: the verdict is in, but the controversy lingers. J. Bone Miner. Res. 1996, 11: 565–567.

    Article  CAS  PubMed  Google Scholar 

  49. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.-C., Shah A.S., Huster W.J., Draper M., Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997, 337: 1641–1647.

    Article  CAS  PubMed  Google Scholar 

  50. Lufkin E.G., Whitaker M.D., Nickelsen T., Argueta R., Caplan R.H., Knickerbocker R.K., Riggs B.L. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J. Bone Miner. Res. 1998, 13: 1747–1754.

    Article  CAS  PubMed  Google Scholar 

  51. Ensrud K., Black D., Recker R., Harris S., Delmas P., Pols H., Reginster J., Bjarnason N., Gennari C., Genant H., Knickerbocker R., Eastell R., Adachi J., Mitlak B. The effect of 2 and 3 years of raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. Bone 1998, 23: S174.

    Google Scholar 

  52. Jordan V.C., Glusman J.E., Eckert S., Lippman M., Powles T., Costa A., Morrow M., Norton L., Lurie R.H. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, doubleblind, randomised trials in 12,000 postmenopausal women. Proc. Am. Soc. Clin. Oncol. 1998, 17: 122a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital, Cambridge, UK

    Juliet Compston M.D.

Authors
  1. Juliet Compston M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juliet Compston M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Compston, J. The role of SERMs in the management of postmenopausal osteoporosis. J Endocrinol Invest 22, 646–652 (1999). https://doi.org/10.1007/BF03343623

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343623

Key-words

Search

Navigation